by Mike Masnick
Thu, Oct 7th 2010 10:34pm
Copycense points us to a NY Times piece about how pharmaceutical giant Eli Lilly is facing some tough times ahead. Why? Because the patents on the drugs that make up most of its revenue are all set to expire soon, and their pipeline of newly patented drugs is pretty far behind. Of course, what this highlights is the folly of relying on patents as your business model. The patents become a crutch, and you're unable to build a real business doing anything other than coming up with new patentable drugs. It takes the focus away from building a real business around making people healthy, to one that's focused on coming up with stuff we can sell that can be patented.
If you liked this post, you may also be interested in...
- EFF Goes To Court To Stop Australian Patent Troll From Stifling Free Speech
- India Learns The Hard Way That Equating Patents And Innovation Comes At A Price
- Stupid Patent Of The Month: Storing Files In Folders
- Eli Lilly Loses Quixotic Quest To Get Canada To Pay $500 Million For Rejecting Its Bad Patents
- Pharma Officials Insist That There Is 'Zero Evidence' That Patents Harm Access To Medicine